Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.23%6 Days Inventory is 34.77 as of Mar. 2026, which is 105% above its 10-year median of 16.93. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, 20/20 Biolabs ranks better than 94.03% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). 20/20 Biolabs's Average Total Inventories for the
three
months ended in Mar. 2026 was $0.11 Mil. 20/20 Biolabs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.29 Mil.
Hence, 20/20 Biolabs's Days Inventory for the
three
months ended in Mar. 2026 was 34.77.
The historical rank and industry rank for 20/20 Biolabs's Days Inventory or its related term are showing as below:
AIDX'
s Days Inventory Range Over the Past 10 Years
Min: 14.16 Med: 16.93 Max: 48.11
Current: 48.11
During the past 3 years, 20/20 Biolabs's highest Days Inventory was 48.11. The lowest was 14.16. And the median was 16.93.
AIDX's Days Inventory is ranked better than 94.03% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 179.47
vs AIDX: 48.11
20/20 Biolabs's Days Inventory
increased
from Dec. 2024 (13.21) to Mar. 2026 (34.77).
It might indicate that 20/20 Biolabs's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
20/20 Biolabs's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.62.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
20/20 Biolabs's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.31.
20/20 Biolabs (NAS:AIDX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
20/20 Biolabs's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
20/20 Biolabs's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
20/20 Biolabs Days Inventory Related Terms
20/20 Biolabs Days Inventory Historical Data
* Premium members only.
The historical data trend for 20/20 Biolabs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIDX vs STME, TRIB, VVOS: Days Inventory Comparison
For the Medical Devices subindustry, 20/20 Biolabs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's Days Inventory distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
20/20 Biolabs (AIDX) has a Days Inventory of 34.77 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on 20/20 Biolabs and its competitors. This is 105% above median its historical median of 16.93. Over the past decade, 20/20 Biolabs' Days Inventory has ranged from 14.16 to 48.11. According to the industry distribution chart, 20/20 Biolabs ranks #47 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 6%.
Is 20/20 Biolabs' Days Inventory too high?
20/20 Biolabs' current Days Inventory of 34.77 is 105% above median its 10-year median of 16.93. Over the past 10 years, this metric has ranged from a low of 14.16 to a high of 48.11. The Medical Devices & Instruments industry median Days Inventory is 179.47. 20/20 Biolabs' value of 34.77 is 80.6% below this industry median. Based on the distribution chart, 20/20 Biolabs ranks #47 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Days Inventory compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #47 out of 787 companies for Days Inventory. This places 20/20 Biolabs in the top 6% of its industry — outperforming the majority of peers. The industry median Days Inventory is 179.47. 20/20 Biolabs' value of 34.77 is 80.6% below this benchmark. Historically, 20/20 Biolabs' own Days Inventory has ranged from 14.16 to 48.11 over the past decade. While the company's 10-year median is 16.93 vs. the industry median of 179.47, 20/20 Biolabs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.47, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 20/20 Biolabs's current Days Inventory of 34.77 is 80.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on 20/20 Biolabs and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current Days Inventory is 34.77, which is 105% above median its own 10-year median of 16.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Days Inventory of 34.77. The current Days Inventory is 34.77, which is 105% above median its 10-year median of 16.93 and 80.6% below the Medical Devices & Instruments industry median of 179.47. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Days Inventory is 34.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
